Smital Shah, MS
Smital Shah is our consulting Chief Financial Officer. She currently is an independent Chief Financial Officer/Chief Business Officer consultant working with multiple biotech and life sciences companies on finance and business development strategy and operations. From October 2014 to December 2022, Ms. Shah served as Chief Business and Financial Officer at a Nasdaq-listed company called ProQR Therapeutics, overseeing all the business functions that included finance, communications, commercial, business development and legal. Previously, Ms. Shah managed the multi-billion-dollar debt, cash and investment portfolios of Gilead Sciences, Inc. Prior to Gilead, she was an investment banker at Leerink Partners and JP Morgan focused on capital raising and strategic transactions in the biotechnology space. Previously, Ms. Shah held various research and development roles at Johnson & Johnson Company. She holds a B.S. in Chemical Engineering from the University of Mumbai, a M.S. in Chemical Engineering. Ms. Shah also serves on the Board of Directors of Pliant Therapeutics and was Board Director and Chair of the Audit Committee at Graphite Bio, until its merger with Lenz Therapeutics in March 2024.